Optos has the vision to be recognized as the leading provider of retinal diagnostics by providing eye care professionals our unique ultra wide-field imaging technology enabling them to enhance their patient care.
Both eye and non-eye diseases often exhibit first in the periphery of the retina and can be difficult to detect clinically with conventional examination equipment and techniques. Optos' devices produce ultra wide-field, high-resolution images of approximately 82 percent of the retina, something no other device is capable of doing. The optomap® images provide practitioners with enhanced clinical information that facilitates the early detection, management and treatment of disorders and diseases such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Further, retinal imaging can show evidence of non-eye or systemic diseases such as hypertension and certain cancers.
The results of a recent clinical study indicate that optomap assisted examinations had 30 percent greater capability to detect retinal lesions over traditional manual exams. As presented at ARVO 2010, the study conducted at the New England College of Optometry included 170 patients between the ages of 31and 65 who first underwent optomap imaging using the P200C device. The patients' eyes were then dilated, and they underwent traditional examinations by two different examiners, one referring to the optomap image in conjunction with the traditional examination. Lesions detected by traditional methods and optomap-assisted examinations were recorded independently and discrepancies were adjudicated by a retinal specialist.
Kristen Brown, O.D., principal investigator to the study, said: "These results confirm what we had seen in our pilot study: that image-assisted ophthalmoscopy enhances our ability to detect retinal pathology. This helps us to make a difference, one patient at a time. This study illustrates that technology can help us to improve the care we give our patients."
Understanding the varied needs in eye care, Optos offers a full range of complementary retinal imaging devices: P200 is concentrated on wellness screening; P200C in the advanced clinical optometry and ophthalmology markets; P200MA supports retinal specialists through an advanced medical angiography procedure. All three devices provide practitioners the benefit of an ultra wide-field view of the retina or alternatively a maximized resolution image of the central pole.
The newest product introduction is the 200Dx, which provides the same ultra wide-field view with enhanced image quality, such as a brighter superior field, a better distribution of light and greater detail in the central pole. Added software features include historical image overlay, a localized magnifier tool, and the ability to capture as a movie file a 3-D animation sequence flying through the patient's pupil to view their optomap image, which can then be e-mailed to the patient. The continued product enhancements of Optos' technology provide an unequalled combination of ultra wide-field retinal imaging, speed and convenience for both practitioner and patient.
Optos plc is headquartered in Dunfermline, Scotland, and was admitted to the Main Market of the London Stock Exchange on Feb. 15, 2006, trading under the symbol OPTS. Optos' North American headquarters is based in Marlborough, Mass. For more information about the company or products, please visit www.optos.com.